UBS Group
VTGN icon

UBS Group’s VistaGen Therapeutics VTGN Stock Holding History

UBS Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Sell
57,830
-20,906
-27% -$12.6K ﹤0.01% 8412
2026
Q1 		$45K Buy
78,736
+26,743
+51% +$16.2K ﹤0.01% 7432
2025
Q4 		$34.4K Buy
51,993
+26,326
+103% +$95.1K ﹤0.01% 7442
2025
Q3 		$91.1K Buy
25,667
+2,854
+13% +$8.53K ﹤0.01% 7186
2025
Q2 		$45.6K Sell
22,813
-2,966
-12% -$6.74K ﹤0.01% 7848
2025
Q1 		$64.4K Sell
25,779
-106,535
-81% -$302K ﹤0.01% 7387
2024
Q4 		$390K Buy
132,314
+122,193
+1,207% +$344K ﹤0.01% 6014
2024
Q3 		$30.5K Sell
10,121
-9,145
-47% -$31.2K ﹤0.01% 7122
2024
Q2 		$67K Buy
19,266
+14,530
+307% +$62.9K ﹤0.01% 6457
2024
Q1 		$25K Buy
4,736
+4,619
+3,948% +$22.2K ﹤0.01% 6818
2023
Q4 		$601 Sell
117
-1,381
-92% -$5.23K ﹤0.01% 8577
2023
Q3 		$7.85K Buy
1,498
+1,381
+1,180% +$6.13K ﹤0.01% 7210
2023
Q2 		$219 Sell
117
-6,459
-98% -$22.6K ﹤0.01% 8373
2023
Q1 		$24.7K Buy
6,576
+488
+8% +$2.56K ﹤0.01% 6928
2022
Q4 		$18.3K Buy
+6,088
New +$22.9K ﹤0.01% 7749
2022
Q3 		– Sell
-782
Closed -$21K – 10980
2022
Q2 		$21K Buy
782
+351
+81% +$12.4K ﹤0.01% 6827
2022
Q1 		$16K Sell
431
-14,462
-97% -$630K ﹤0.01% 7761
2021
Q4 		$871K Buy
14,893
+7,786
+110% +$507K ﹤0.01% 4511
2021
Q3 		$585K Buy
7,107
+7,099
+88,738% +$617K ﹤0.01% 4623
2021
Q2 		$1K Sell
8
-352
-98% -$26.1K ﹤0.01% 9198
2021
Q1 		$23K Sell
360
-310
-46% -$20.7K ﹤0.01% 7249
2020
Q4 		$39K Sell
670
-6
-0.9% -$153 ﹤0.01% 6407
2020
Q3 		$14K Sell
676
-1,908
-74% -$39.5K ﹤0.01% 6598
2020
Q2 		$41K Buy
2,584
+1,629
+171% +$22.3K ﹤0.01% 6042
2020
Q1 		$13K Buy
955
+285
+43% +$5.22K ﹤0.01% 6786
2019
Q4 		$14K Sell
670
-159
-19% -$4.02K ﹤0.01% 7104
2019
Q3 		$27K Buy
829
+312
+60% +$6.95K ﹤0.01% 6553
2019
Q2 		$11K Buy
+517
New +$13.7K ﹤0.01% 7033
2019
Q1 		– Sell
-278
Closed -$13K – 8207
2018
Q4 		$13K Sell
278
-92
-25% -$5.01K ﹤0.01% 7106
2018
Q3 		$16K Buy
+370
New +$15K ﹤0.01% 6936
2018
Q2 		– Sell
-443
Closed -$12K – 8283
2018
Q1 		$12K Buy
+443
New +$16.5K ﹤0.01% 6768
2017
Q4 		– Sell
-6
Closed – – 8126
2017
Q3 		$0 Sell
6
-197
-97% -$10.4K ﹤0.01% 8018
2017
Q2 		$11K Buy
+203
New +$11.9K ﹤0.01% 6729
2017
Q1 		– Sell
-35
Closed -$4K – 8013
2016
Q4 		$4K Buy
35
+9
+35% +$1.05K ﹤0.01% 7339
2016
Q3 		$3K Buy
+26
New +$2.82K ﹤0.01% 7305

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
RS
R Squared Central, Hong Kong $190M AUM 25.89% 1-Year Est. Return

UBS Group's VTGN Position: Q2 2026 in Review

UBS Group reduced its VistaGen Therapeutics (VTGN) stake by 27% in Q2 2026, selling an estimated $12.6K and leaving 57,830 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #8412.

UBS Group first reported a position in VTGN in Q3 2016 and has held it in 35 quarters since. The position peaked at $871K in Q4 2021. 25 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • UBS Group held 57,830 shares of VistaGen Therapeutics worth $13.1K as of Q2 2026.
  • UBS Group sold 20,906 VistaGen Therapeutics shares in Q2 2026, an estimated $12.6K.
  • VistaGen Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8412 holding.
  • UBS Group first reported a position in VistaGen Therapeutics in Q3 2016 and has held it in 35 quarters since.
  • UBS Group's VistaGen Therapeutics position peaked at $871K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.